PITTSTON, ME--(Marketwire - Feb 15, 2013) - YaFarm Technologies, Inc. ( PINKSHEETS : YFRM ) (YaFarm, or the Company) is pleased to announce that The Integrative Stem Cell Institute (ISCI), a premier provider of point-of-care, stem cell-based therapies, has submitted its complete protocols for the treatment of chronic and degenerative diseases to the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS).
ISCI submitted the protocols for independent evaluation and review of its safety study in the use of adipose derived progenitor (stem) cells in the treatment of chronic and degenerative diseases. The IRB will study ISCI's procedures for harvesting, processing, and re-implanting the patient's own stem cells to confirm patients are not put at risk. The IRB will also review the scientific and medical qualifications of the investigators, the informed consent and patient candidacy forms, and the rationale for the study.
The ICSS IRB is registered with the Office for Human Research Protections, which is a part of the U.S. Department of Health and Human Services. The IRB is comprised of both medical and scientific experts, as well as informed community members, and is managed by the International Cell Surgical Society, a California based physician organization dedicated to education, advancing research, and advocating for cell-based regenerative medicine.
The studies ISCI submitted for approval will be conducted within its state-of-the art laboratory and the fully integrative medical facility of the ISCI, housed in the Hospital Galenia in Cancun, Mexico. As part of the submission, the ISCI will also provide the IRB with the methodology for providing long-term follow up and the conditions specific metrics and safety data that will be collected for review. This model includes the use of the international physician network, the ISCP, to provide independent collection of patient outcomes.
"IRB submission and review is a critical element of our clinical studies programs," says David Audley, CEO of the ISCI. "Many clinics do not take this extra step, but we genuinely believe that patient safety only comes through transparency and oversight. The most effective way we will be able to advance this field, and to deliver on the promise of regenerative medicine, is collect patient data, report it, and publish it," Mr. Audley continued, "We are excited about this important step and look forward to working with the IRB."
About The Integrative Stem Cell Institute (ISCI)The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at http://www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.
Go here to read the rest:
YaFarm Technologies Announces ISCI IRB Submission